My Cart [ 0 ]
Home > Antibodies > Research-Grade Biosimilars > Ipilimumab Biosimilar, CTLA-4 Monoclonal Antibody

Ipilimumab Biosimilar, CTLA-4 Monoclonal Antibody

cytotoxic T-lymphocyte?associated antigen 4, cytotoxic T-lymphocyte antigen 4, CD152, CTLA4

Catalog No. Product Name Size List Price (US$) Quantity
C050P Ipilimumab Biosimilar, Human CTLA-4 Monoclonal Antibody 1 mg 175.00
Description

C050P: Ipilimumab Biosimilar, CTLA-4 Monoclonal Antibody

Recombinant fully human IgG1 monoclonal antibody.
Isotype: Human IgG1 kappa.
Source: The anti-human CTLA-4 monoclonal antibody ipilimumab biosimilar was produced in the ipilimumab biosimilar CHO stable cell line.
Specificity/Sensitivity: The in vivo grade ipilimumab biosimilar specifically binds to the human CTLA4.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by ipilimumab.
Form of Antibody: 0.2 uM filtered solution, pH 7.0, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.

Shipping: The research grade ipilimumab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

Background

What is Ipilimumab biosimilar research grade? Ipilimumab is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma.

Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.

Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is an inhibitory molecule that competes with the stimulatory CD28 for binding to B7 on antigen presenting cells. CTLA-4 and CD28 are both presented on the surface of T-cells. Ipilimumab is a human IgG1 that binds CTLA-4, preventing the inhibition of T-cell mediated immune responses to tumors.

Syd Labs provides the following research grade anti-CTLA-4 antibody biosimilars:
Ipilimumab Biosimilar, research grade, anti-human CTLA-4 monoclonal antibody
Tremelimumab Biosimilar, research grade, anti-human CTLA-4 monoclonal antibody

PD-1 is a member of the extended CD28/CTLA-4 family of T cell regulators. Syd Labs provides the following research grade anti-PD-L1 / PD-1 antibody biosimilar proteins:
Atezolizumab biosimilar, research grade, anti-human PD-L1 monoclonal antibody
Avelumab biosimilar, research grade, anti-human PD-L1 monoclonal antibody
Camrelizumab biosimilar, research grade, anti-human PD-1 monoclonal antibody
Cemiplimab biosimilar, research grade, anti-human PD-1 monoclonal antibody
Durvalumab biosimilar, research grade, anti-human PD-L1 monoclonal antibody
Nivolumab biosimilar, research grade, anti-human PD-1 monoclonal antibody
Pembrolizumab biosimilar, research grade, anti-human PD-1 monoclonal antibody
Spartalizumab biosimilar, research grade, anti-human PD-1 monoclonal antibody

Related Links

See our Privacy Policy